Zacks: Brokerages Expect Odonate Therapeutics Inc (NASDAQ:ODT) to Announce -$1.08 EPS
Analysts expect Odonate Therapeutics Inc (NASDAQ:ODT) to post ($1.08) earnings per share (EPS) for the current quarter, Zacks Investment Research reports. Zero analysts have issued estimates for Odonate Therapeutics’ earnings. The highest EPS estimate is ($1.01) and the lowest is ($1.14). Odonate Therapeutics reported earnings of ($1.17) per share in the same quarter last year, which would indicate a positive year-over-year growth rate of 7.7%. The company is expected to announce its next quarterly earnings results on Friday, February 28th.
On average, analysts expect that Odonate Therapeutics will report full-year earnings of ($4.23) per share for the current year, with EPS estimates ranging from ($4.30) to ($4.16). For the next fiscal year, analysts anticipate that the business will post earnings of ($4.73) per share, with EPS estimates ranging from ($5.21) to ($4.25). Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of research firms that follow Odonate Therapeutics.
A number of research firms recently weighed in on ODT. BidaskClub lowered shares of Odonate Therapeutics from a “buy” rating to a “hold” rating in a research report on Friday. Goldman Sachs Group began coverage on shares of Odonate Therapeutics in a research report on Friday, December 6th. They set a “sell” rating and a $26.00 price target on the stock. Finally, Zacks Investment Research lowered shares of Odonate Therapeutics from a “buy” rating to a “hold” rating in a research report on Tuesday, November 12th. Two equities research analysts have rated the stock with a sell rating, two have assigned a hold rating and one has assigned a buy rating to the stock. The company currently has an average rating of “Hold” and an average target price of $29.00.
A number of large investors have recently bought and sold shares of the business. Redmile Group LLC boosted its holdings in Odonate Therapeutics by 4.4% in the 3rd quarter. Redmile Group LLC now owns 773,571 shares of the company’s stock valued at $20,136,000 after purchasing an additional 32,900 shares during the last quarter. Driehaus Capital Management LLC boosted its holdings in Odonate Therapeutics by 26.4% in the 4th quarter. Driehaus Capital Management LLC now owns 664,459 shares of the company’s stock valued at $21,562,000 after purchasing an additional 138,737 shares during the last quarter. BlackRock Inc. boosted its holdings in Odonate Therapeutics by 55.4% in the 2nd quarter. BlackRock Inc. now owns 578,823 shares of the company’s stock valued at $21,236,000 after purchasing an additional 206,238 shares during the last quarter. Eagle Asset Management Inc. boosted its holdings in Odonate Therapeutics by 5.3% in the 3rd quarter. Eagle Asset Management Inc. now owns 528,124 shares of the company’s stock valued at $13,747,000 after purchasing an additional 26,811 shares during the last quarter. Finally, Vanguard Group Inc. boosted its holdings in Odonate Therapeutics by 23.5% in the 2nd quarter. Vanguard Group Inc. now owns 447,411 shares of the company’s stock valued at $16,416,000 after purchasing an additional 85,133 shares during the last quarter. Institutional investors own 97.96% of the company’s stock.
About Odonate Therapeutics
Odonate Therapeutics, Inc, a pharmaceutical company, develops therapeutics for the treatment of cancer. It is developing tesetaxel, an orally administered chemotherapy agent, which is in Phase III clinical study for patients with locally advanced or metastatic breast cancer. The company was founded in 2013 and is based in San Diego, California.
Recommended Story: How Do You Make Money With Penny Stocks?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Odonate Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Odonate Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.